Introduction {#S0001}
============

Recently, colorectal cancer (CRC) has become the third most frequent malignant tumor worldwide and the fourth deadliest cancer due to recurrence and metastasis.[@CIT0001] In China, patients diagnosed as advanced CRC account for approximately 6--8% of malignancies. Accumulating evidence has confirmed that the overall survival (OS) and recurrence-free survival (RFS) of patients with locally advanced CRC can be improved through perioperative chemotherapy besides surgical resection (R0).[@CIT0002]--[@CIT0004] Regardless of improvements of surgical methods and combined chemotherapeutic regimens, the prognostic outcomes remain unsatisfactory.[@CIT0005] Conventionally, clinical and pathological characteristics, including high cancer stage, inadequate sampling from lymph nodes, poorly differentiated histology and lymph-vascular invasion, have been identified as significant risk factors for poor prognosis.[@CIT0006] The guidelines of the National Comprehensive Cancer Network (NCCN) recommend using adjuvant chemotherapy to prevent postoperative tumor recurrence. However, these traditional markers may sometimes be incapable of accurate prediction of the prognosis. Therefore, it is of great significance to find easily available and reliable prognostic factors for distinguishing high-risk cases and providing the optimum chemotherapeutic strategy, aiming to further enhance the therapeutic effects.

Several retrospective studies have revealed that adjuvant chemotherapy caused severer systemic inflammatory reaction and weaker adaptive immune response, bringing about an imbalance between inflammation and malignant tumor to stimulate cancer progression and recurrence.[@CIT0007],[@CIT0008] Predictive peripheral blood factors of inflammatory response include counts of neutrophils, white blood cells, monocytes, lymphocytes and platelets, together with expressions of acute-phase proteins. Moreover, platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are well-known biomarkers closely associated with the survival of patients with biliary tract cancer, gastric cancer, ovarian cancer and CRC.[@CIT0009]--[@CIT0012] Nevertheless, the roles of the two inflammatory indices remain controversial.[@CIT0013],[@CIT0014]

To verify the predictive values of these biomarkers, we proposed a novel prognostic scoring system (coNLR-PLR) that combined NLR with PLR to evaluate the prognosis of CRC patients more accurately. We then employed this system to explore the potential role in augmenting the predictive capacity for the prognosis of chemotherapy.

Materials and methods {#S0002}
=====================

The study has been approved by the ethics committee of No. 3 Hangzhou People's Hospital, and was performed in compliance with the standards of the Declaration of Helsinki. Before the study started, written informed consent has been obtained from all patients.

Selection of patients {#S0003}
=====================

A total of 480 patients with primary CRC, who received postoperative FOLFOX-based chemotherapy in Department of Colorectal Surgery, No. 3 Hangzhou People's Hospital from January 2007 to January 2013, were enrolled and retrospectively analyzed. Inclusion criteria: (1) Patients who received surgical resection for CRC and were pathologically defined as TNM stage III/IV; (2) without hematological diseases, infections, renal dysfunction or hyperpyrexia; (3) without using drugs including NSAIDs; (4) without inflammation-related diseases or vascular disorders; (4) without receiving radiotherapy, chemotherapy or any other targeted therapies.

Protocol for adjuvant chemotherapy according to NCCN guidelines {#S0004}
===============================================================

All patients received adjuvant chemotherapy with the FOLFOX regimen according to the NCCN guidelines. FOLFOX regimen: 85 mg/m^2^ oxaliplatin, 200 mg/m^2^ calcium levofolinate and 400 mg/m^2^ bolus 5-fluorouracil (5-FU), all on day 1; infusion with 2,400 mg/m^2^ 5-FU on days 1--3. The regimen was performed once every 2 weeks, 12 cycles in total.

Clinical, pathological and laboratory data {#S0005}
==========================================

To determine the predictive value, we collected the clinical, pathological and laboratory data of patients before receiving the 1st, 4th, 8th and 12th cycles of adjuvant chemotherapy. The clinical and pathological characteristics, such as gender, age, body mass index (BMI), as well as tumor site, differentiation, TNM stage and histological type, were collected from the medical records. Laboratory measurements were performed on the day before chemotherapy, which included counts of neutrophils, white blood cells, lymphocytes and platelets, as well as expressions of some biochemical factors such as serum carbohydrate antigen 199 (CA199), carcinoembryonic antigen (CEA) and C-reactive protein (CRP). Furthermore, the ratio of absolute count of neutrophils to that of lymphocytes was defined as NLR, and the ratio of absolute count of platelets to that of lymphocytes was defined as PLR.

NLR and PLR scoring method {#S0006}
==========================

Based on the optimum cut-off value obtained from the receiver operating characteristic (ROC) curve, the score of NLR was 1 or 0 when patient had a high or low NLR during each chemotherapy. Likewise, the score of PLR was 1 or 0 in the case of a high or low PLR. During the same period of chemotherapy, coNLR-PLR, ie, the combined score, was assigned a score of 1 when patient had a high NLR or PLR and a score of 0 when both values were low. Also, the score was 2 in the case of two high values. Therefore, the scores throughout the four periods of chemotherapy ranged from 0 to 8 scores. The coNLR-PLR scores during one period were defined as the sum of NLR and PLR scores.

Follow-up data of survival prognosis {#S0007}
====================================

Patients were regularly followed up through telephone calls and letters every 3--6 months until deadline or death. Colonoscopy and computed tomography were conducted at appointments during follow-up. Death was informed by outpatient medical records, social security death index of patient or notification from the family members. The time from the first day of palliative chemotherapy to recurrence or disease progression was defined as RFS, and the time from the first day of palliative chemotherapy to the last follow-up or death because of any reason was defined as OS. Follow-up was ended after January 1, 2018.

Statistical analysis {#S0008}
====================

The best cut-off values for PLR and NLR as predictive markers for OS were determined by ROC analysis with the You-den Index. The association between PLR and NLR was analyzed by linear regression. The associations between coNLR-PLR score and pathological and clinical characteristics were assessed by the Fisher's exact probability test or Chi-square test. To study prognosis, the Kaplan--Meier method was employed to calculate PFS and OS, with the differences compared by the log-rank test. Univariate and multivariate analyses were carried out by using the Cox proportional hazards model with 95% confidence interval to evaluate the effect of the above-mentioned characteristics and some significant prognostic factors (eg, PLR and NLR). *P*≤0.05 was considered statistically significant. All analyses were conducted using SPSS 11.5 for Windows.

Results {#S0009}
=======

Patient characteristics and outcomes {#S0009-S2001}
------------------------------------

[Table 1](#T0001){ref-type="table"} summarizes the detailed clinical and pathological characteristics together with laboratory parameters of the 480 eligible patients. The average age was (62.7±18.19) years old, and the male/female ratio was 1.39. Of these patients, 297 and 183 were diagnosed as primary rectal cancer and colon cancer, respectively. Besides, 63.13% of the CRC patients were at stage III and 36.87% were at stage IV. The maximum size of primary lesion in 155 patients was 5 cm, and most tumors presented poorly differentiated histology (G3/G4) (59.79%). Most lesions of 281 patients (58.54%) reached an invasive depth of T3, and 203 patients (42.29%) were subjected to local nodal metastasis (≥2). The positive expression rates of serum CEA and CA199 were 60.21% and 53.13%, respectively. According to nutritional indices, a majority of the patients had normal BMI (65%) and high level of albumin (67.08%). With regard to laboratory parameters, the abnormal percentages of neutrophils, white blood cells, platelets, lymphocytes and CRP were 37.91%, 56.04%, 37.29%, 48.75% and 61.04%, respectively.Table 1Relationships between clinical characteristics and coNLR-PLRCharacteristicsTotal n=480Score 0 n=28Score 1 n=39Score 2 n=47Score 3 n=56Score 4 n=69Score 5 n=74Score 6 n=72Score 7 n=50Score 8 n=45*P*Age (years)0.235 \<60221181519313133372116 ≥60259102428253841352929BMI (kg/m^2^)^1^0.237 Normal312192830404547363532 High/low16891117162427361513Gender0.468 Male279172328343350373126 Female201111619223624351919Location0.393 Colon183111220183523271918 Rectal297172727383451453127Tumor size(cm)0.374 \<5325152933384156463532 ≥5155131014182818261513Cancer stage0.015 III303202935384839423421 IV17781012182135301624Cancer grade0.015 G1/G2193182222252728221514 G3/G4287101725314246503531Tumor invasion\<0.001 T3281182934424931322125 T4199101013142043402920Lymph node metastasis0.457 \<2277152328343350373126 ≥2203131619223624351919CEA (ng/ml)^2^0.013 \<5289172634384844302923 ≥5191111313182130422122CA199 (kU/L)^3^0.140 \<35225122026352433322122 ≥35255161921214541402923Albumin (g/dL)0.193 \<3.5158151718172125201312 ≥3.5322132229394849523733WBC count (×10^9^/L)^4^0.424 Normal211162222272931301717 High/low269121725294043423328Neutrophil count (×10^9^/L)0.038 Normal298172430414852412421 High/low182111517152122312624Lymphocyte count (×10^9^/L)0.309 Normal246181420313142352316 High/low234101719253832372729Platelet count (×10^9^/L)0.074 Normal301202733414544452521 High/low17981214152430272524CRP (mg/L)^5^0.025 Normal187182022242221241917 High293101925324753483128[^1]

Analysis of coNLR-PLR scoring system {#S0009-S2002}
------------------------------------

Based on ROC curves, the optimum cut-off values of PLR and NLR for OS divided into four periods of chemotherapy were calculated ([Figure 1](#F0001){ref-type="fig"}). The optimum cut-off values of NLR were 3.029, 2.466, 2.102 and 1.795, respectively, and those of PLR were 216.438, 187.572, 169.027 and 174.368, respectively ([Table 2](#T0002){ref-type="table"}). Clearly, these values gradually dropped, but the AUC values hardly changed. Then, linear regression analysis was performed to study whether there was significant correlation between NLR and PLR in each period (*P*\<0.001) ([Figure 2](#F0002){ref-type="fig"}). Furthermore, NLR scores were more closely associated with coNLR-PLR scores during chemotherapy ([Figure 3](#F0003){ref-type="fig"}).Table 2Combined score of NLR-PLR by ROC curve analysisNLRPRLAUC95%CI*P*Cut-offHighLowAUC95%CI*P*Cut-offHighLow1st Chemotherapy0.7250.637--0.736\<0.0013.0292512090.6460.594--0.699\<0.001216.1382342264th Chemotherapy0.6860.590--0.693\<0.0012.4662372230.6370.585--0.690\<0.001187.5722192418th Chemotherapy0.7020.601--0.709\<0.0012.1022212390.6560.605--0.708\<0.001160.02722623412th Chemotherapy0.6730.632--0.734\<0.0011.7952032570.5830.583--0.686\<0.001174.368198262[^2] Figure 1Receiver operating characteristic curve analysis for OS and RFS between NLR and PLR in four periods of chemotherapy. (**A**) For NLR, the optimal cut-off values were 3.029, 2.466, 2.102 and 1.795 in periods of chemotherapy. (**B**) For PLR, the optimal cut-off values, respectively, were 216.138, 187.572, 160.027 and 171.368 in periods of chemotherapy.**Abbreviations:** NLR, neutrophil-to-lymphocyte; PLR, platelet-to-lymphocyte; ROC, receiver operating characteristic; AUC, area under the curve.Figure 2Linear regression of NLR and PLR during the four periods of adjuvant chemotherapy. (**A**) During the 1st period, the linear correlation coefficient of NLR and PLR was 0.672 and *P*-value was less than 0.001. (**B**) During the 4th period, the linear correlation coefficient of NLR and PLR was 0.622 and *P*-value was less than 0.001. (**C**) During the 12th period, the linear correlation coefficient of NLR and PLR was 0.781 and *P*-value was less than 0.001.**Abbreviations:** RFS, recurrence-free survival; OS, overall survival; BMI, body mass index; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen; WBC, white blood cells; CRP, C-reactive protein; coNLR-PLR, combined neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio.Figure 3Distribution between score and chemotherapy period. (**A**) According to the four periods, NLR score curve was closer to coNLR-PLR than PLR. (**B**) According to the coNLR-PLR score, distribution of the number of patients was in each score.**Abbreviations:** OS, overall survival; BMI, body mass index; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen; WBC, white blood cells.

Relationships of clinical characteristics with coNLR-PLR scores {#S0009-S2003}
---------------------------------------------------------------

[Table 1](#T0001){ref-type="table"} lists the baseline clinical characteristics according to coNLR-PLR scores. The age, BMI, gender, lymph node metastasis, tumor site and size, CA199 level, albumin level, white blood cell count, lymphocyte count and platelet count of all groups were similar (*P*\>0.05). In contrast, cancer stage, grade, invasion, serum CEA level, neutrophil count and CRP level were significantly associated with coNLR-PLR scores (*P*\<0.05). In detail, the patients with high scores had high cancer stage, grade, invasive capacity, serum CEA level, neutrophil count and CRP level. Collectively, high coNLR-PLR scores were closely related with poor prognosis.

Survival prognosis for each coNLR-PLR score {#S0009-S2004}
-------------------------------------------

According to the follow-up results, 184 (38.33%) patients underwent recurrence, of whom 54 and 130 were subjected to local recurrence and distant metastasis, respectively. Additionally, 201 (44.79%) patients were dead due to tumor recurrence (169 cases), chemotherapeutic toxicity (2 cases) and unknown reasons. [Table 3](#T0003){ref-type="table"} lists the relationships of clinical characteristics with prognosis of RFS and OS. High cancer stage (IV), severe invasion (T4), abnormal neutrophil count (high/low) and evaluated coNLR-PLR scores had significant associations with poor OS and RFS (*P*\<0.05). As suggested by the log-rank test and Kaplan--Meier curve, the median OS was significantly shortened with increasing coNLR-PLR score (*P*\<0.001) ([Figure 4A](#F0004){ref-type="fig"}). Similarly, the median RFS also decreased as the coNLR-PLR score increased (*P*\<0.001) ([Figure 4B](#F0004){ref-type="fig"}). Thus, patients can be effectively differentiated using the coNLR-NLR scoring system.Table 3Association of clinical baseline characteristics with RFS and OSCharacteristicsTotal n=480RFS n(%) of recurrence*P*-valueOS n(%) of deaths*P*-valueAge (years)0.7460.231 \<6022183 (45.11%)99 (49.25%) ≥60259101 (54.89%)102 (50.75%)BMI (kg/m^2^)0.3860.749 Normal312124 (67.39%)129 (64.18%) High/low16860 (32.61%)72 (35.82%)Gender0.6960.365 Male279109 (59.24%)112 (55.72%) Female20175 (40.76%)89 (44.28%)Location0.1850.160 Colon18377 (41.85%)84 (41.79%) Rectal297107 (58.15%)117 (58.21%)Tumor size (cm)0.4720.072 \<5325121 (65.76%)127 (63.18%) ≥515563 (34.24%)74 (36.82%)Cancer stage\<0.001\<0.001 III30393 (50.54%)86 (42.79%) IV17791 (49.46%)115 (57.21%)Cancer grade0.0130.198 G1/G219361 (33.15%)74 (36.82%) G3/G4287123 (66.85%)127 (63.18%)Tumor invasion0.0150.019 T328195 (51.63%)104 (51.74%) T419989 (48.37%)95 (47.26%)Lymph node metastasis0.0810.134 \<227797 (52.72%)108 (53.73%) ≥220387 (47.28%)93 (46.27%)CEA (ng/ml)0.0920.703 \<5289102 (55.43%)119 (59.20%) ≥519182 (44.57%)82 (40.80%)CA199 (kU/L)0.3720.551 \<3522591 (40.44%)91 (40.44%) ≥3525593 (50.54%)110 (43.14%)Albumin (g/dL)0.4930.534 \<3.515864 (34.78%)63 (31.34%) ≥3.5322120 (65.22%)138 (68.66%)WBC count (×10^9^/L)0.0850.107 Normal21190 (48.91%)97 (48.26%) High/low26994 (51.07%)104 (51.74%)Neutrophil count (×10^9^/L)0.0180.025 Normal298102 (55.43%)113 (56.22%) High/low18282 (44.57%)88 (43.78%)Lymphocyte count (×10^9^/L)0.0020.197 Normal246111 (60.33%)96 (47.76%) High/low23473 (39.67%)105 (52.24%)Platelet count (×10^9^/L)0.1520.855 Normal301108 (58.70%)127 (63.18%) High/low17976 (41.30%)74 (36.82%)CRP (mg/L)0.3670.483 Normal18767 (36.41%)82 (40.80%) High293117 (63.59%)119 (59.20%)CoNLR-PLR\<0.001\<0.001 Score 0286 (3.26%)5 (2.48%) Score 1398 (4.35%)10(4.98%) Score 24713 (7.07%)15 (7.46%) Score 35618 (9.78%)16 (7.96%) Score 46919 (10.33%)22 (10.95%) Score 57429 (15.76%)33 (16.42%) Score 67231 (16.85%)34 (16.92%) Score 75028 (15.22%)31 (15.42%) Score 84532 (17.38%)35 (17.41%)[^3] Figure 4Comparison of survival prognosis in each coNLR-PLR score. (**A**) For overall survival, patients with higher had poorer prognosis (log-rank *p*\<0.001). (**B**) For recurrent-free survival, patients with higher had poorer prognosis (log-rank *p*\<0.001).**Abbreviations:** RFS, recurrence-free survival; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen; WBC, white blood cells; CRP, C-reactive protein.

Independent prognostic value of elevated coNLR-PLR score for poor survival {#S0009-S2005}
--------------------------------------------------------------------------

Univariate and multivariate analyses were carried out for various parameters to identify independent factors for survival prognosis ([Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}). Univariate analysis revealed that high cancer stage, low differentiation grade, severe invasion, lymph node metastasis, serum CEA level, neutrophil count and raised coNLR-PLR score were all significantly associated with both OS and RFS (*P*\<0.05). Platelet count and serum CA199 were significantly associated with RFS (*P*\<0.05) but not OS. Nevertheless, lymphocyte count was significantly associated with OS (*P*=0.037) instead of RFS. Subsequently, the significant factors (*P*\<0.05) in univariate analysis were included in the Cox proportional hazards model for multivariate analysis. High cancer stage, severe invasion, lymph node metastasis and increased coNLR-PLR score had significant associations with poor prognosis of RFS and OS (*P*\<0.05).Table 4Prognostic factors associated with OS in univariate and multivariate analysisCharacteristicsUnivariate analysisMultivariate analysisHR95% CI*P*HR95% CI*P*Age (years)1.0240.7131.470.721BMI (kg/m^2^)1.9820.9721.4330.511Gender0.9350.6481.3480.412Location0.9330.6441.3520.214Tumor size (cm)0.8620.5851.270.453Cancer stage2.3331.2643.907\<0.0012.3831.4543.9070.001Cancer grade2.5451.0764.716\<0.0012.9930.783.4230.082Tumor invasion1.6492.9624.423\<0.0010.4460.0030.0940.011Lymph node metastasis2.9062.6623.73\<0.0012.0511.2234.1410.024CEA (ng/ml)1.3691.9592.4510.0211.0450.9711.2490.223CA199 (kU/L)1.3790.8191.8410.342Albumin (g/dL)1.5270.9112.1590.534WBC count (×10^9^/L)1.2810.6991.8470.493Neutrophil count (×10^9^/L)2.1121.4313.7660.0021.4620.8552.1430.249Lymphocyte count (×10^9^/L)1.9611.5743.4970.0371.0410.7441.9530.201Platelet count (×10^9^/L)1.1740.9441.7310.322CRP (mg/L)0.9140.8511.5640.291CoNLR-PLR ScoresScore 00.9351.5122.7420.559Score 11.3121.3342.7530.453Score 20.9971.4122.3160.361Score 31.1031.0242.2120.237Score 41.0880.9721.7240.422Score 51.1221.0432.0190.371Score 61.0331.0122.0190.0130.7840.4271.6390.349Score 72.3192.0174.324\<0.0010.4360.141.3630.016Score 82.0291.3314.123\<0.0013.1121.6244.379\<0.001[^4] Table 5Prognostic factors associated with RFS in univariate and multivariate analysisCharacteristicsUnivariate analysis for RFSMultivariate analysis for RFSHR95% CI*P*HR95% CI*P*Age (years)1.0130.7051.4570.643BMI (kg/m^2)^1.0880.7451.5880.463Gender0.9710.6731.4010.475Location0.970.6691.4070.373Tumor size (cm)0.9180.6231.3530.665Cancer stage2.4491.6753.581\<0.0012.5111.3054.1310.009Cancer grade2.0611.1753.6890.0071.620.7422.7710.383Tumor invasion6.3334.4299.932\<0.0011.0490.9141.9910.043Lymph node metastasis3.522.4065.152\<0.0010.9110.7691.5530.007CEA (ng/ml)2.9011.6513.7410.0011.6111.1022.7310.219CA199 (kU/L)2.1210.9744.3220.0411.0030.8711.9420.119Albumin (g/dL)1.7040.7481.5440.199WBC count (×10^9^/L)1.0040.6791.4450.283Neutrophil count (×10^9^/L)2.0061.6963.4530.0251.4130.7222.690.317Lymphocyte count (×10^9^/L)1.7171.3362.5320.391Platelet count (×10^9^/L)2.3221.4214.4020.0042.0171.5524.7540.001CRP (mg/L)0.9970.8761.5430.279CoNLR-PLR ScoresScore 01.2831.0312.7340.371Score 11.0720.9431.8610.452Score 21.5291.0422.9430.461Score 32.1181.5413.1420.393Score 41.2551.0032.2480.319Score 51.0580.8571.9420.0372.1011.2713.5620.181Score 61.0211.0072.6450.0131.461.0033.5190.049Score 71.0581.022.7890.0081.8291.0973.0120.102Score 81.7210.9733.061\<0.0012.5511.3353.9060.019[^5]

Discussion {#S0010}
==========

Because of persistent response to chronic inflammation, some predictive biomarkers can dynamically indicate the survival prognosis of patients receiving adjuvant chemotherapy.[@CIT0015] Cell factors in the peripheral blood, such as NLR and PLR, typically reflect the inflammatory status.[@CIT0016],[@CIT0017] In this study, we proposed a novel index combining NLR with PLR, which could accurately predict the survival prognosis of CRC patients receiving FOLFOX-based chemotherapy.

Researchers have endeavored to unravel the mechanisms for the inflammatory responses of malignant tumors for decades.[@CIT0018] The growth of tumor cells promotes the necrosis, hypoxia and injury of local tissues, thereby disturbing the homeostasis and activating immune responses. As a result, IL-1, IL-6, IL-8, vascular endothelial growth factor, tumor necrosis factor and some other pro-inflammatory cytokines are secreted by tumor cells and/or inflammatory cells related with tumors. These cytokines thereafter result in tumor growth, angiogenesis, metastasis and invasion, reverse adaptive immune responses, and boost the resistance to cytotoxic substances.[@CIT0019],[@CIT0020] Notably, elevated PLR and NLR were accompanied by increase of platelet and neutrophil counts but decrease of lymphocyte count, indicating that inflammatory responses associated with platelets and neutrophils were enhanced and the antitumor immune responses mediated by lymphocytes were attenuated.

In the presence of inflammatory signals, neutrophils are activated quickly and migrate to inflammatory sites.[@CIT0021] Because of chronic inflammation, the persistent stimulus to neutrophils aggravates oxidative stress that damages the epithelium and induces pro-mutagenic DNA lesions.[@CIT0022] Besides, neutrophils may suppress lymphocyte activity upon antitumor immune responses and promote remodeling of the extracellular matrix.[@CIT0023],[@CIT0024] Herein, neutrophil count was significantly associated with prognosis only in univariate analysis.

Baseline platelet count has been recognized as an index of chemotherapy prognosis for advanced CRC.[@CIT0025] Aggregation of platelets in the circulation is able to protect tumor cells from immune surveillance and shear stress by forming platelet cloaks.[@CIT0026] Moreover, chemoresistance can be triggered by platelets throughout epithelial--mesenchymal transition, direct protection, anti-apoptotic pathways mediated by PAI-1 or immunosuppression regulated by NKG2-D down-regulation.[@CIT0027] We herein assessed the predictive value of platelet count in CRC patients receiving chemotherapy, which was an independent factor for RFS only in univariate analysis.

Additionally, lymphocytes play an important role in antitumor immune responses.[@CIT0028] By changing the tumor microenvironment, lympho-depletion probably contributes to the attenuation of intestinal tumorigenesis and anti-tumor immune responses.[@CIT0029],[@CIT0030] Furthermore, lymphopenia has also been linked to elevated circulating IL-7 level that facilitates lymphangiogenesis, tumor proliferation, and metastasis.[@CIT0031] Hence, the CRC chemotherapy-related lymphopenia in this study may be partly explained.

Given that these inflammatory indices are intrinsically correlated, NLR and PLR before treatment are significant factors for predicting the responses of a variety of cancers to chemotherapy.[@CIT0032] Nevertheless, using only one index may bring about bias and risk in detection. Therefore, we employed a coNLR-PLR scoring system to analyze RFS and OS more accurately during four periods of FOLFOX-based chemotherapy. The coNLR-PLR score was calculated by adding up continuous cycles of optimum cut-off values according to ROC curve analysis, unlike the Glasgow prognostic score with three stratifications (0, 1 and 2)[@CIT0033] To the best of our knowledge, this is a rare study regarding the association between coNLR-PLR score and the prognosis of CRC patients receiving chemotherapy. This index was a significant independent prognostic factor, and a higher one suggested poorer prognosis for RFS and OS. Also, the coNLR-PLR scoring system was superior to NLR or PLR alone.

Similar to the results of literature before, factors related with cancer stage and invasion besides coNLR-PLR were also identified by univariate and multivariate analyses as significant prognostic indices.[@CIT0034],[@CIT0035] However, only univariate analysis showed that serum CEA and CA199 levels had associations with poor prognosis, which was contrary to a previous study.[@CIT0036] This inﬂammatory biomarker, which is facilely detectable, simple, objective, economical and reproducible, can be tested at the beginning of chemotherapy and dynamically monitored throughout the treatment process.[@CIT0037] As a complicated model, coNLR-PLR may provide more reliable prognostic evidence for clinicians.

Regardless, this study still has limitations. First, it is a single-center retrospective study. In addition, prospective studies are in need to clarify whether the proposed index can be incorporated into the stratification systems for patients with cancers to individualize treatment regimens.

Conclusion {#S0011}
==========

In summary, we proposed a coNLR-PLR scoring system, as a novel index correlated independently with survival prognosis, and verified that peripheral blood cells dominantly bridged the interaction between cancer and host during adjuvant chemotherapy. Nevertheless, these findings ought to be validated by in-depth prospective studies.
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[^1]: **Abbreviations:** BMI, body mass index; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen; WBC count, white blood cell count; CRP, C-reactive protein; coNLR-PLR, combined neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio.

[^2]: **Abbreviations:** OS, overall survival; RFS, recurrence-free survival; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

[^3]: **Abbreviations:** NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

[^4]: **Abbreviations:** NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; coNLR-PLR, combined NLR ratio and PLR ratio.

[^5]: **Abbreviation:** coNLR-PLR, combined neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio.
